Richland Firm Introduces Promising Isotope For Cancer Treatment; Prostate Cancer Patient Receives New Seed Therapy By IsoRay Medical, Inc. In A Worldwide First For Cesium-131

A new isotope for low-dose (LDR) seed brachytherapy was implanted into a prostate cancer patient at the University of Washington Medical Center today, marking the first brachytherapy seed implant in the world utilizing the radioactive isotope Cesium-131. This new isotope represents the first major advancement in LDR seed brachytherapy in more than 18 years.